Emai:marketing@yakkaa.com
業務谘詢專線:400-780-8018
Tel: +1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
地址:上海市浦東新區川大路585號
郵編:201299
電話:+86 (21) 5859-1500(總機)
傳真:+86 (21) 5859-6369
© 2023 上海hjc黄金城生物醫藥股份有限公司 保留所有權利 滬ICP備10216606號-3
滬公網安備 31011502018888號 | 網站地圖
業務谘詢
中國:
Email: marketing@yakkaa.com
業務谘詢專線:400-780-8018
(僅限服務谘詢,其他事宜請撥打川沙總部電話)
川沙總部電話: +86 (21) 5859-1500
海外:
+1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Y180, an orally available Mpro inhibitor, is effective against wild-type SARS-CoV-2 and variants. Y180 displayed satisfying PK properties in mice, rats and dogs, with oral bioavailabilities of 92.9%, 31.9% and 85.7%, respectively. The in vivo PK properties of Y180 were evaluated. All procedures related to animal handling, care and treatment in PK studies were performed according to approved guidelines. The PK studies were approved by the Ethics Committee of Medicilon.
Reference:
Bao-Xue Quan, et al. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Nat Microbiol. 2022 May;7(5):716-725. doi: 10.1038/s41564-022-01119-7.